• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2026, Vol. 43 ›› Issue (3): 226-226-230.doi: 10.2095-3593.2026.060003

• 临床研究 • 上一篇    下一篇

甲磺酸萘莫司他在血液透析患者中的抗凝效果与安全性评价

 陈晨, 龚雪莲, 黄燕, 沈青云*   

  1. 启东市人民医院, 启东肝癌防治研究所, 南通大学附属启东医院, 江苏 南通 226200
  • 收稿日期:2026-01-07 修回日期:2026-03-11 接受日期:2026-08-05 出版日期:2026-06-28 发布日期:2026-08-12

Evaluation of the Anticoagulant Efficacy and Safety of Nafamostat Mesylate in Hemodialysis Patients

CHEN Chen, GONG Xuelian, HUANG Yan, SHEN Qingyun*   

  1. Qidong Hospital, Affiliated to Nantong University, Jiangsu Nantong 226200, China
  • Received:2026-01-07 Revised:2026-03-11 Accepted:2026-08-05 Online:2026-06-28 Published:2026-08-12

摘要: 目的:探讨甲磺酸萘莫司他(nafamostat mesylate,NM)在血液透析患者体内的抗凝作用与安全性状况。方法:2023年1月至2024年8月我院接受血液透析的100例患者被随机分为观察组(NM)和对照组(标准抗凝剂肝素),每组各50例。分别对两组患者的抗凝效果、凝血功能、酸碱平衡及电解质水平进行比较。结果:观察组的抗凝总有效率为90.0%,高于对照组的60.0%(P<0.001)。观察组透析器和管路内纤维蛋白沉积较少,凝血功能更为稳定(P>0.05)。透析后2、4 h,观察组患者体内APTT明显延长(P<0.05)。观察组透析后4 h凝血功能均优于对照组(P<0.05)。透析前后pH、Na+、K+等酸碱平衡和电解质水平以及出血并发症在两组间差异无统计学意义(P>0.05)。结论:NM在血液透析中的抗凝效果优于传统抗凝剂,且安全性高。NM能够有效预防透析过程中纤维蛋白沉积,保持透析器的通透性,减少出血风险。

关键词: font-size:medium, ">血液透析;甲磺酸萘莫司他;抗凝效果;安全性;凝血功能

Abstract: Objective: To evaluate the anticoagulant efficacy and safety of nafamostat mesylate (NM) in patients undergoing hemodialysis. Methods: A total of 100 patients undergoing hemodialysis in our hospital between January 2023 and August 2024 were randomly assigned to either the observation group (NM) or the control group (standard anticoagulant heparin), with 50 patients in each group. The anticoagulant efficacy, coagulation function, acid-base balance, and plasma electrolyte levels were compared between the two groups. Results: The total effective rate of anticoagulation in the observation group was 90.0%, higher than that of the control group(60.0%) (P<0.001). The observation group showed less fibrin deposition in the dialyzer and tubing, and more stable coagulation function (P>0.05). The APTT in vivo of the observation group was significantly prolonged at 2, 4 h after dialysis (P<0.05). The coagulation function of the observation group was better than that of the control group 4 h after dialysis (P<0.05). There was no statstic difference in pH, Na+, K+and other acid-base balance, electrolyte levels, and bleeding complications between the two groups before and after dialysis (P>0.05). Conclusion: Nafamostat mesylate demonstrates superior anticoagulant efficacy compared to traditional anticoagulants in hemodialysis, with a higher safety profile. NM effectively prevents fibrin deposition during dialysis, maintains the patency of the dialyzer, and reduces bleeding risks.

Key words: font-size:medium, ">Hemodialysis; Nafamostat mesylate; Anticoagulant efficacy; Safety; Coagulation function

中图分类号: